CBIZ, Inc. Form 8-K Summary
Business Context and Reporting Period
On July 30, 2024, CBIZ, Inc. (CBZ) filed a Current Report on Form 8-K to disclose the entry into a definitive Agreement and Plan of Merger with Marcum LLP. The filing date is July 30, 2024, with the report dated July 31, 2024. CBIZ is a provider of business advisory, tax, and accounting services.
Key Financial Metrics and Transaction Terms
This filing details a material acquisition rather than periodic financial results. Key transaction metrics include:
- Total Consideration: Approximately $2.3 billion on a cash-free, debt-free basis.
- Cash Component: Approximately $1.1 billion.
- Stock Component: Approximately 14.4 million shares of CBIZ Common Stock (valued at $76.84 per share, representing the 30-day VWAP).
- Share Dilution: The new shares will constitute approximately 22% of CBIZ's outstanding shares upon full issuance.
- Financing: CBIZ has secured a $2.0 billion credit facility commitment from Bank of America, N.A. and BofA Securities, Inc., consisting of a $600 million revolving credit facility and a $1.4 billion term loan.
Material Changes and Transaction Structure
The transaction involves a two-part structure:
- The Merger: CBIZ will acquire Marcum's non-attest business assets via a merger with Marcum Advisory Group LLC (MAG). MAG will become a wholly-owned subsidiary of CBIZ.
- The Attest Purchase: In a separate transaction, Mayer Hoffman McCann P.C. will purchase Marcum's attest business assets.
The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Guidance, Outlook, Risks, and Contingencies
Closing Conditions: The deal is contingent upon regulatory approvals (including HSR Act), CBIZ stockholder approval, Marcum partner approval, and the successful completion of the Attest Purchase.
Termination Fees:
- CBIZ Liability: $48.0 million if debt financing is not obtained; $25.0 million if stockholder approval is not obtained or the board changes its recommendation.
- Marcum Liability: $22.0 million if requisite partner approval is not obtained within the specified timeframe.
Share Delivery Schedule:
- 5% subject to performance/service requirements (delivered on the fourth anniversary).
- 25% delivered on the later of three business days post-closing or January 2, 2025.
- 75% delivered in 36 monthly installments.
Risks: Management highlights risks regarding the ability to consummate the transaction, regulatory delays, integration challenges, increased leverage, and the potential failure to achieve anticipated synergies.
Investor Verification Checklist
- Verify the final terms of the $2.0 billion credit facility and the interest rate/fees associated with the increased leverage.
- Monitor the status of regulatory approvals under the Hart-Scott-Rodino Act and the completion of the separate Attest Purchase by Mayer Hoffman McCann P.C.
- Review the definitive proxy statement for details on the stockholder vote required to approve the issuance of approximately 14.4 million new shares.
- Assess the impact of the 22% share dilution on earnings per share (EPS) and the specific vesting conditions for the 5% performance shares.
- Confirm the timeline for the fourth-quarter 2024 closing and any potential extensions beyond the May 1, 2025 termination date.